Such regional variations in disease prevalence must be taken into account when assessing a drugs possible prohibition, Rabin says
The demyelinating process is accompanied, amongst other factors, by extensive neuroinflammation (Gold et al., 2006)
however, delayed inhibition after the inflammatory peak preserves normal healing
[DOI] [PubMed] [Google Scholar] 88.Clifford GM, Londos C, Kraemer FB, Vernon RG, Yeaman SJ
The following is the typical dosing schedule for weeks 5-16: Weeks 5-8: 0.5 mg (semaglutide) / 0.5 mcg (vitamin B12) once weekly Weeks 9-12: 1.0 mg (semaglutide) / 0.5 mcg (Vitamin B12) once weekly Weeks 13-16: 1.7 mg (semaglutide) / 0.5 mcg (Vitamin B12) once weekly Weeks 17 onwards: 2.5 mg (semaglutide) / 0.5 mcg (Vitamin B12) once weekly, if further weight loss is required